- active not recruitingPHASE1, PHASE2
Durvalumab and Tremelimumab for Pediatric Malignancies
This study is testing new drug combinations to treat children and teenagers with advanced cancer. We're looking for the safest and most effective dose of these immunotherapy drugs, durvalumab and tremelimumab, for solid and blood cancers.
United States · France · Germany - active not recruitingPHASE2
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, teclistamab, for people with multiple myeloma that has come back or hasn't responded to other treatments. It's looking at how well the medicine works at a specific dose.
United States · Belgium · Canada - recruitingNA
APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU
This study looks at how exercise and relaxation can help reduce anxiety for people with blood cancer in intensive care. It explores different types of exercise and relaxation, including special games and a technique called biofeedback, to see which works best.
France - recruitingPHASE1, PHASE2
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
This study looks at a new treatment called SMART101 for adults with blood cancers who are having a specific type of stem cell transplant. It aims to see if SMART101 is safe and helps their immune system recover faster after the transplant.
France - recruitingPHASE2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine, talquetamab, for people with multiple myeloma that has come back or isn't responding to other treatments. The main goal is to see how well it works and if it's safe at the recommended doses.
United States · Belgium · China - active not recruitingPHASE1, PHASE2
Study of AZD9829 in CD123+ Hematological Malignancies
This study is testing a new medicine called AZD9829 for people in the UK with certain blood cancers where other treatments haven't worked or stopped working. Researchers want to see if it's safe and effective, given alone or with other treatments, for cancers that have a specific marker called CD123.
United States · Australia · China - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
This study is testing a new medicine called DS3790a for blood cancers. It's an early-stage trial looking at how safe the medicine is, what side effects it might cause, and if it helps people get better. We're also checking how well different ways of giving the medicine work.
France · Italy